Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
Depression and anxiety are the prevalent nonmotor symptoms that worsen quality of life for Parkinson's disease (PD) patients. Although dopamine (DA) cell loss is a commonly proposed mechanism, the reported efficacy of DA replacement therapy with L-DOPA on affective symptoms is inconsistent. To delineate the effects of DA denervation and chronic L-DOPA treatment on affective behaviors, male Sprague-Dawley rats received unilateral 6-hydroxydopamine or sham lesions and were treated daily with L-DOPA (12 mg/kg+benserazide, 15 mg/kg, subcutaneously) or vehicle (0.9% NaCl, 0.1% ascorbic acid) for 28 days before commencing investigations into anxiety (locomotor chambers, social interaction) and depression-like behaviors (forced swim test) during the OFF phase of L-DOPA. One hour after the final treatments, rats were killed and striatum, prefrontal cortex, hippocampus, and amygdala were analyzed through high-performance liquid chromatography for monoamine levels. In locomotor chambers and social interaction, DA lesions exerted mild anxiogenic effects. Surprisingly, chronic L-DOPA treatment did not improve these effects. Although DA lesion reduced climbing behaviors on day 2 of exposure to the forced swim test, chronic L-DOPA treatment did not reverse these effects. Neurochemically, L-DOPA treatment in hemiparkinsonian rats reduced norepinephrine levels in the prefrontal cortex, striatum, and hippocampus. Collectively, these data suggest that chronic L-DOPA therapy in severely DA-lesioned rats does not improve nonmotor symptoms and may impair nondopaminergic processes, indicating that long-term L-DOPA therapy does not exert necessary neuroplastic changes for improving affect.
Eskow Jaunarajs
Karen L
KL
Behavioral Neuroscience Program, Department of Psychology, State University of New York at Binghamton, Binghamton, New York, USA.
Dupre
Kristin B
KB
Ostock
Corinne Y
CY
Button
Thomas
T
Deak
Terrence
T
Bishop
Christopher
C
D000679:Amygdala / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001007:Anxiety / Q000188:drug therapy; D035841:Behavioral Research; D015306:Biogenic Monoamines / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000378:metabolism / Q000473:pathology; D003863:Depression / Q000188:drug therapy; D004298:Dopamine / Q000031:analogs & derivatives / Q000502:physiology; D015259:Dopamine Agents / Q000627:therapeutic use; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D023421:Models, Animal; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D016627:Oxidopamine / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D017397:Prefrontal Cortex / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
D015306:Biogenic Monoamines; D015259:Dopamine Agents; D007980:Levodopa; D016627:Oxidopamine; D004298:Dopamine